Successful Psilocybin Treatment of Alzheimer

This case report details the remarkable, albeit temporary, functional improvements observed in an octogenarian woman suffering from advanced Alzheimer's disease following the administration of psilocybin-containing mushrooms. For years, the patient experienced severe cognitive decline, including monosyllabic speech, incontinence, and dependency. The study aims to explore if neuromodulatory conditions can access residual functional capacity in late-stage neurodegeneration, a condition usually considered irreversible.<ul><li>An 80-year-old Japanese-American woman with 10 years of Alzheimer's, including 5 years of severe hypofunction, received 5 grams of Enigma strain psilocybin mushrooms.</li><li>The acute phase involved a prolonged deep sleep-like state, followed by spontaneous autobiographical speech 19 hours later.</li><li>Over subsequent days and weeks, she showed significant improvements: restoration of urinary continence, improved ambulation, autonomous dressing, increased emotional responsiveness, sustained social interaction, contextual memory retrieval, and spontaneous conversational engagement.</li><li>One month later, a second 3g dose was administered, leading to further verbal expressivity, humor, and agility.</li><li>The improvements were transient, and the study emphasizes that this does not imply disease reversal but rather a temporary accessibility of latent functional capacities.</li><li>Limitations include the single-case design, lack of formal biomarker confirmation, and quantitative measurements, making causality impossible to establish.</li></ul>In conclusion, this single case suggests psilocybin might transiently unlock latent functional abilities in advanced Alzheimer's patients, highlighting the need for systematic, controlled investigation into its neuromodulatory effects, despite the clear methodological limitations of this initial report.